



International PfSPZ Consortium Meeting

Building Cure, Seattle Children's, 1920 Terry Ave. Seattle, WA 98101

Day 1: Thursday 03 November 2022

Time	Subject	Presenter(s)
13:00	Log on to Zoom	
13:15	Welcome	Eric James / LW Preston Church
13:20	Introduction to the Meeting	Stephen Hoffman
13:25	Opening remarks	Stefan Kappe/Alassane Dicko/Marcel Tanner
Directions for PfSPZ vaccines		
13:40	WHO update: Status of Malaria Vaccine Introduction and Pipeline	Mary Hamel
13:50	Sanaria progress and strategies	Stephen Hoffman
14:10	Discussion	Moderators: Pedro Alonso
14:20	Welcome to Seattle Children's	Eric Tham
Late Arresting Replication Competent (LARC) PfSPZ vaccines		
14:30	Discovery path to late liver stage arresting replication competent (LARC) parasites	Ashley Vaughan
14:42	Safety and protective efficacy of PfΔmei2-SPZ (PfSPZ-GA2) in humans administered by mosquito bite	Blandine Franke-Fayard
14:54	Development of PyLARC2 and mouse studies	Ashley Vaughan / Stefan Kappe
15:02	Development of PfSPZ-LARC2 (Pfmei2/PfLINUP) and FRG mouse studies	Stefan Kappe
15:10	GMP manufacture and QC release of PfSPZ-LARC2 Vaccine	Kim Lee Sim
15:18	Design of and plans for the first PfSPZ-LARC2 Vaccine clinical trial	Andrea Kreidenweiss
15:26	Design of and plans for the second PfSPZ-LARC2 Vaccine clinical trial	Sean Murphy
15:31	Pre-IND questions, submissions and FDA responses: timeline for IND and IMPD submissions	Tooba Murshedkar
15:36	Plans for field trials in Africa in children and women of child bearing potential	Thomas Richie
15:44	Overview of PfSPZ-LARC2 Vaccine development pathway and clinical development plans	Thomas Richie
15:49	Discussion	Moderators: Meta Roestenberg, Ashley Vaughan, Pedro Alonso
16:04	Coffee	
PfSPZ vaccines for pregnancy and malaria		
16:19	Background on the overall program of studies of pregnancy malaria in Ouelessebouyou	Patrick Duffy/Alassane Dicko
16:29	Pregnancy malaria burden in O'bougou, including role of "asymptomatic" infection on fetal/maternal disease	Michal Fried
16:36	Findings from Mali-3 and -4 (Phase 2) PfSPZ trials including impact of parasitemia and need for presumptive	Halimatou Diawara
16:48	Insights from immunological analyses in WOCBP and other trials	Irfan Zaidi
16:56	Design of Phase 1 and 2 trials in pregnant women	Sara Healy
17:02	Regulatory pathway to PfSPZ vaccine licensure with pregnancy malaria prevention as a vaccine indication	Tooba Murshedkar
17:07	Clinical pathway to PfSPZ vaccine licensure with pregnancy malaria prevention as a vaccine indication	Tom Richie
17:13	Discussion	Moderators: Rose Leke / Flor Munoz-Rivas / Alisa Kachikis
Recently completed, ongoing and planned clinical trials: PfSPZ Vaccine and PfSPZ-CVac		
17:28	Warfighter 3 : completed	Jim Kublin
17:38	Warfighter 3 discussion	Moderator: Benjamin Mordmueller
17:43	Mali 5: ongoing (Phase 2)	Issaka Sagara
17:50	IDSPZV1 - Indonesian soldiers: ongoing (Phase 2)	Erni Nelwan
17:57	USSPZ7	LW Preston Church
18:02	Discussion	Moderators: Martin Grobusch, Sean Murphy
18:17	Open Discussion	LW Preston Church / Eric James
18:27	Closing remarks	Stephen Hoffman
Consortium Group Photograph		
19:00	Dinner: Tutta Bella Italian Restaurant - 2200 Westlake Ave #112, Seattle, WA 98121 The restaurant is a 6-10 minute walk from the meeting venue. Directions will be provided as needed.	



International PfSPZ Consortium Meeting

Building Cure, Seattle Children's, 1920 Terry Ave. Seattle, WA 98101

Day 2: Friday 04 November 2022

Time	Subject	Presenter(s)
7:00	Breakfast	
7:15	Log on to Zoom	
7:15	Introduction to the day	Stephen Hoffman
7:20	Comments on direction and progress	Peter Kreamsner
The funders' perspective		
7:25	Introduction and overview	Stephen Hoffman
7:30	NIAID-NIH	Lee Hall/Annie Mo
7:35	EDCTP	Pauline Beattie
7:40	Prince Ned Nwoko Malaria Eradication Project	Prince Ned Nwoko/Anyaduba Chuks
7:45	TBD	Tahir Gozal
7:50	Malaria vaccine funding: the BMGF perspective	Jean-Luc Bodmer
7:55	Discussion	Moderators: Annie Mo, Chuks Anyaduba
Clinical and parasitological monitoring and endpoints		
8:10	Quick review of Plasmodium 18S rRNA/rDNA FDA Biomarker Qualification for non-endemic CHMI studies	Sean Murphy
8:20	Proposed guidelines on the VALIDATION of 18S rRNA/rDNA biomarker assays (Guideline #1)	Meta Roestenberg, Sean Murphy
8:25	Panel discussion regarding ASSAY VALIDATION	Panel: Matt Laurens, Jason Regules, Scott Miller, Claudia Daubenberg, Albert Lalremruata
8:30	Proposed guidelines on the use of 18S rRNA/rDNA biomarker CHMI UNTIL TREATMENT (study schedule & treatment threshold) (Guidelines #2 and #3)	Meta Roestenberg, Sean Murphy
8:40	Panel discussion regarding CHMI UNTIL TREATMENT	Panel: Matt Laurens, Jason Regules, Scott Miller, Claudia Daubenberg, Albert Lalremruata
8:45	Proposed guidelines on the use of 18S rRNA/rDNA biomarker POST-TREATMENT (Guideline #4)	Meta Roestenberg, Sean Murphy
8:50	Panel discussion regarding POST-TREATMENT	Panel: Matt Laurens, Jason Regules, Scott Miller, Claudia Daubenberg, Albert Lalremruata
8:55	Open Q&A	All
9:00	Development of multiple specimen device for rapid PCR	Tobias Schindler
9:07	Comparison of ultrasensitive and standard RDT diagnostic techniques	Max Mpina
9:14	Clinical versus parasitological endpoints for clinical studies	Greg Deye
9:21	Discussion:	Moderators: Tom Richie/Patrick Duffy
9:36	Coffee	
Manufacturing without mosquitoes: In vitro-produced PfSPZ (iPfSPZ)		
9:51	Overview and progress with iPfSPZ	Stephen Hoffman
10:11	Discussion	Moderators: Freddy Frischknecht, Abraham Eappen
Improving vaccine efficacy and efficiency		
10:21	Introduction	Stephen Hoffman
10:24	Improving vaccine efficacy and efficiency through use of a glycolipid adjuvant	Sumana Chakravarty
10:29	Improving vaccine efficacy and efficiency by the prime and trap and role of replicating RNA	Felicia Watson/Sean Murphy/Steve Reed
10:36	Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasites (U01) / The creation of effective pan-African genetically attenuated Plasmodium falciparum sporozoite (PfSPZ) vaccines using experimental genetic crosses.	Kim Lee Sim/Ashley Vaughan/Joana da Silva/Lucia Pazzagli/Ehud Inbar/Bethany Jenkins
10:56	Parasite populations from Equatorial Guinea	Tom Stabler
11:01	Advances in P. berghei-based malaria vaccination	Miguel Prudencio
11:08	Late liver stage drugs for CVac	Justin Boddey
11:13	Discussion	Moderators: Lee Hall / Joana Silva



International PfSPZ Consortium Meeting

Building Cure, Seattle Children's, 1920 Terry Ave. Seattle, WA 98101

Day 2 Continued: Friday 04 November 2022

Monoclonal antibodies as immunoprophylaxis

11:28	General overview of progress and plans	Stephen Hoffman
11:33	Results of clinical trials	Peter Crompton
11:45	Plans for clinical trials: Update from Gates Malaria Institute	Scott Miller
11:50	The Sanaria-Regeneron collaboration to develop and commercialize mAbs	Stephen Hoffman
11:53	Discussion	

Moderators: Patrick Duffy / Peter Crompton

Updates from PfSPZ Challenge CHMI studies

12:08	PfSPZ Challenge (NF54) CHMI in Kenya reveals that Dantu blood group variant provides high level protection against uncomplicated malaria	Silvia Kariuki
12:14	Use of PfSPZ Challenge (NF54) CHMI in Mali for assessing transmission blocking immunity	
12:20	TransMod - Use of PfSPZ Challenge (NF54) CHMI in Kenya for assessing transmission blocking immunity	Matthew McCall/Issaka Sagara/Katherine Collins Melissa Kapulu
12:26	Discussion	Moderators: Meta Roestenberg, Said Jongo

12:37 Lunch

Progress and plans for PkSPZ and PvSPZ Challenge studies

13:37	Progress and plans for PkSPZ Challenge - Sanaria	Sumana Chakravarty
13:42	The PkSPZ model in pigtailed macaques for malaria vaccine evaluation	Sean Murphy / Melanie Shears
13:47	Progress and plans for PvSPZ Challenge	Patrick Duffy, Sumana Chakravarty, Stefan Kappe, Sean Murphy
14:02	Discussion	Moderators: L W Preston Church

Immunology

13:37	Systems serology identification of correlates of protection in PfSPZ Vaccine trial	Jonathan Herman
13:52	Increased levels of anti-PfCSP antibodies in post-pubertal females versus males immunized with PfSPZ Vaccine does not translate into increased protective efficacy	Natasha KC
14:00	Identification of KLRC1+ V δ 2 γ δ T cells as a correlate of PfSPZ Vaccine efficacy	Irfan Zaidi
14:06	Correlates of protection	Jim Kublin
14:12	Protective Immune responses in IMRAS	Ken Stuart
14:18	Single cell analysis of immune cell populations following malaria challenge infection	Suzanne McDermott
14:24	Protective Targets of PfSPZ-based whole organism vaccines identified from genome-wide sieve analyses of Pf isolates from field efficacy trials	Ankit Dwivedi
14:30	Update on systems analysis of the KSPZV1 vaccine trial	Tuan Tran
14:36	Discussion	Moderators: Jim Kublin / Sumana Chakravarty

Battleship Sporozoites

14:51	PfSPZ as a eukaryotic cell platform technology for delivery of foreign antigens	Stephen Hoffman
-------	---	-----------------

Close out session

14:56	Open discussion	LW Preston Church / Eric James
15:11	Final remarks	Stephen Hoffman

9 min (0.4 mile)

via 7th Ave and Stewart St
Mostly flat



Use caution—walking directions may not always reflect real-world conditions

Seattle Convention Center

705 Pike St, Seattle, WA 98101

↑ Head southwest on Pike St toward 7th Ave

52 ft

➔ Turn right onto 7th Ave

0.2 mi

➔ Turn right onto Stewart St


0.2 mi

➤ Turn left onto Terry Ave

128 ft

Seattle Children's Research Institute: Building Cure

1920 Terry Ave, Seattle, WA 98101



5 min (0.3 mile)

via Terry Ave
Mostly flat

⚠ Use caution—walking directions may not always reflect real-world conditions

Seattle Children's Research Institute: Building Cure

1920 Terry Ave, Seattle, WA 98101

↑ Head northwest on Terry Ave toward Virginia St

302 ft

↶ Turn left onto Virginia St

161 ft

↷ Turn right toward Lenora St

427 ft

↷ Turn right onto Lenora St

167 ft

↶ Turn left onto Terry Ave

180 ft

↶ Turn left

30 ft

Walk for 210 ft

210 ft

↑ Head southwest

📍 Destination will be on the right

10 ft

Tutta Bella Neapolitan Pizzeria - South Lake Union

2200 Westlake Ave #112, Seattle, WA 98121

